FILING ANALYSIS · MONDAY, NOVEMBER 16
Aptevo Therapeutics Inc. APVO — 8-K: Results of Operations and Financial Condition
positive
Aptevo Therapeutics reports a 79% remission rate for Mipletamig in high-risk TP53-mutated AML, nearly double the historical benchmark, and announces progress in optimizing treatment tolerability and advancing its next-generation cancer treatment pipeline.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →